Oncology therapeutics continue to lead FDA and EMA approvals year over year, with drug discovery services in oncology predicted to have a 15% CAGR by 2025 [Ref 1; IQVIA]. Regardless of your tissue or tumor type focus, or whether your therapeutic approach involves small molecules, antibody-drug conjugates (ADCs), or immunotherapies, Eurofins Discovery has the in vitro models needed to advance both monotherapies and combination approaches in the fight against cancer.[see graph below from Global Cancer Observatory, IQVIA].
Our translational oncology and immuno-oncology models help you:
- understand which oncology indication may be most suitable for your candidate, based on cancer type or genomic features
- determine the immuno-oncology potential of your molecule
- benchmark new molecules against clinical drugs, tool compounds, or your own program’s reference agent
Our in vitro models include OncoPanel® 2D and 3D options, BioMAP® tumor microenvironment options, and cell migration assays. With OncoPanel Services, you can benefit from 300+ immortalized human tumor cell lines, licensed from renowned repositories, for a breadth of in vitro oncology models to use in cancer drug candidate screening and profiling:
- Cellular health, proliferation, and functional readouts
- Predictive genomic biomarker identification
- 100+ 3D spheroid cancer cell line options
With drug combination profiling, kinase and gene-focused screening panels, and long-term culture for epigenetic strategies, we are sure to have a service to match your needs.
Our BioMAP Oncology Panels include tumor microenvironment and immuno-oncology models, with translational protein biomarkers as endpoint readouts, and predictive analytical tools to test drug candidates and benchmark to standards of care. BioMAP Oncology models are validated with clinically approved anticancer drugs and immunotherapies.
- Human PBMCs in co-culture with early passage primary human fibroblasts or endothelial cells, as well as cancer cells, model the complexity of the tumor microenvironment
- Robust assays recapitulate tumor-immune-stromal or tumor-immune-vascular microenvironments and disease-relevant interactions and signaling pathways that occur during tumorigenesis
Using confocal high-content analysis, you can evaluate the impact of your test agent on human fibrosarcoma cell migration. Highly metastatic HT1080 human fibrosarcoma cells are tested using the cell exclusion zone method to provide reliable, reproducible results. Assays can be adapted to different tumor cell models, with validation, and multicolor staining is available as a custom service for those interested in mechanism-of-action investigations using multiplex readouts.
- Small molecule and biologics treatments are applicable
- Closure area more precisely controlled compared to traditional scratch assays
- Automatic image segmentation and data analysis provide rich information and unbiased quantification
How to choose?
- I want to evaluate direct anticancer effects > choose OncoPanel
- I want to assess tumor microenvironment impact or immuno-oncology potential > choose BioMAP
- I want to visualize and quantitate impacts on tumor cell migration > choose cell migration
